EVERSANA welcome you to a breakfast program that examines best practices to expand into the U.S. market. The pharmaceutical pipeline is gaining momentum, led by many first-time launchers. But the reality is companies spend more than $200 million over three years leading up to launch, and 66% of drugs still don’t meet launch expectations.
- Trends in U.S. Biopharma, MedTech and DTx launches
- Explore differences between commercialisation models: launching with EVERSANA, traditional licensing or launching on your own
- Optimizing launch sequence across markets in Europe and globally
Read more and register here.